Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWRNYSEARCA:LABDNYSEARCA:LABUNASDAQ:MDGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$12.27-3.7%$17.99$12.14▼$30.41$1.68B0.921.34 million shs1.03 million shsLABDDirexion Daily S&P Biotech Bear 3x Shares$10.42+10.5%$7.32$4.78▼$11.41$58.77M-2.4316.89 million shs10.52 million shsLABUDirexion Daily S&P Biotech Bull 3x Shares$54.57-10.5%$84.37$53.69▼$152.60$500.88M3.011.43 million shs2.55 million shsMDGLMadrigal Pharmaceuticals$324.78-1.9%$333.68$189.00▼$377.46$7.17B-0.41399,823 shs125,989 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals-7.81%-17.81%-32.63%-32.23%-55.45%LABDDirexion Daily S&P Biotech Bear 3x Shares+11.73%+28.83%+26.75%+30.07%+29.36%LABUDirexion Daily S&P Biotech Bull 3x Shares-11.73%-24.39%-25.94%-32.26%-54.06%MDGLMadrigal Pharmaceuticals+1.02%-4.38%-2.94%+7.34%+24.04%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARWRArrowhead Pharmaceuticals3.4441 of 5 stars3.31.00.03.42.72.50.0LABDDirexion Daily S&P Biotech Bear 3x SharesN/AN/AN/AN/AN/AN/AN/AN/ALABUDirexion Daily S&P Biotech Bull 3x SharesN/AN/AN/AN/AN/AN/AN/AN/AMDGLMadrigal Pharmaceuticals3.4467 of 5 stars2.40.00.04.62.24.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 2.60Moderate Buy$41.44237.77% UpsideLABDDirexion Daily S&P Biotech Bear 3x Shares 0.00N/AN/AN/ALABUDirexion Daily S&P Biotech Bull 3x Shares 2.76Moderate Buy$53.96-1.11% DownsideMDGLMadrigal Pharmaceuticals 2.80Moderate Buy$378.4416.52% UpsideCurrent Analyst Ratings BreakdownLatest LABU, MDGL, ARWR, and LABD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/27/2025MDGLMadrigal PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy$236.00 ➝ $422.002/27/2025MDGLMadrigal PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$378.00 ➝ $469.002/27/2025MDGLMadrigal PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$400.00 ➝ $405.002/14/2025ARWRArrowhead PharmaceuticalsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$51.00 ➝ $38.002/12/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.002/11/2025ARWRArrowhead PharmaceuticalsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$42.00 ➝ $42.002/11/2025ARWRArrowhead PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.001/23/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.001/14/2025MDGLMadrigal PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$390.00 ➝ $400.001/10/2025MDGLMadrigal PharmaceuticalsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$427.00 ➝ $427.00(Data available from 4/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$2.50M673.95N/AN/A$1.54 per share7.97LABDDirexion Daily S&P Biotech Bear 3x SharesN/AN/AN/AN/AN/AN/ALABUDirexion Daily S&P Biotech Bull 3x SharesN/AN/AN/AN/AN/AN/AMDGLMadrigal Pharmaceuticals$180.13M39.81N/AN/A$20.53 per share15.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$599.49M-$5.17N/AN/AN/AN/A-236.60%-64.09%5/8/2025 (Estimated)LABDDirexion Daily S&P Biotech Bear 3x SharesN/AN/A0.00∞N/AN/AN/AN/AN/ALABUDirexion Daily S&P Biotech Bull 3x SharesN/AN/A0.00∞N/AN/AN/AN/AN/AMDGLMadrigal Pharmaceuticals-$373.63M-$22.11N/AN/AN/AN/A-71.78%-53.25%5/6/2025 (Estimated)Latest LABU, MDGL, ARWR, and LABD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/26/2025Q4 2024MDGLMadrigal Pharmaceuticals-$4.32-$2.71+$1.61-$2.71$97.81 million$103.32 million2/10/2025Q1 2025ARWRArrowhead Pharmaceuticals-$0.42-$1.39-$0.97-$1.39$19.05 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/ALABDDirexion Daily S&P Biotech Bear 3x Shares$0.343.26%N/AN/AN/ALABUDirexion Daily S&P Biotech Bull 3x Shares$0.260.48%N/AN/AN/AMDGLMadrigal PharmaceuticalsN/AN/AN/AN/AN/ALatest LABU, MDGL, ARWR, and LABD DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date1/15/2025LABDDirexion Daily S&P Biotech Bear 3x Shares$0.05463/25/20253/25/20254/1/20251/15/2025LABUDirexion Daily S&P Biotech Bull 3x Shares$0.10713/25/20253/25/20254/1/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals7.276.096.09LABDDirexion Daily S&P Biotech Bear 3x SharesN/AN/AN/ALABUDirexion Daily S&P Biotech Bull 3x SharesN/AN/AN/AMDGLMadrigal Pharmaceuticals0.155.985.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%LABDDirexion Daily S&P Biotech Bear 3x SharesN/ALABUDirexion Daily S&P Biotech Bull 3x SharesN/AMDGLMadrigal Pharmaceuticals98.50%Insider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals4.30%LABDDirexion Daily S&P Biotech Bear 3x SharesN/ALABUDirexion Daily S&P Biotech Bull 3x SharesN/AMDGLMadrigal Pharmaceuticals22.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400137.32 million120.68 millionOptionableLABDDirexion Daily S&P Biotech Bear 3x SharesN/A5.62 millionN/ANot OptionableLABUDirexion Daily S&P Biotech Bull 3x SharesN/A9.22 millionN/ANot OptionableMDGLMadrigal Pharmaceuticals9022.08 million16.84 millionOptionableLABU, MDGL, ARWR, and LABD HeadlinesRecent News About These CompaniesPictet Asset Management Holding SA Buys 57,886 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)March 31 at 4:54 AM | marketbeat.comNEOS Investment Management LLC Decreases Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)March 31 at 4:36 AM | marketbeat.comArtisan Partners Limited Partnership Trims Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)March 29 at 5:21 AM | marketbeat.comAmerican Century Companies Inc. Grows Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)March 29 at 4:10 AM | marketbeat.comIs Madrigal Pharmaceuticals (MDGL) The Most Expensive Stock Insiders Are Dumping In March?March 28, 2025 | insidermonkey.comMadrigal (MDGL) Up 0.5% Since Last Earnings Report: Can It Continue?March 28, 2025 | zacks.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $378.44 Average PT from BrokeragesMarch 26, 2025 | americanbankingnews.comKnights of Columbus Asset Advisors LLC Buys 2,116 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)March 24, 2025 | marketbeat.comCibc World Markets Corp Makes New $519,000 Investment in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)March 23, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Average Recommendation of "Moderate Buy" from AnalystsMarch 23, 2025 | marketbeat.comMadrigal Pharmaceuticals (MDGL): Among the Best Biotech Stocks to Buy According to BillionairesMarch 18, 2025 | msn.comWilliam Blair Investment Management LLC Purchases Shares of 371,771 Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)March 18, 2025 | marketbeat.comRaymond James Financial Inc. Takes $16.62 Million Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)March 18, 2025 | marketbeat.comSkandinaviska Enskilda Banken AB publ Has $2.43 Million Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)March 17, 2025 | marketbeat.comProficio Capital Partners LLC Acquires New Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)March 17, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $46.52 Million Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)March 15, 2025 | marketbeat.comMadrigal Pharmaceuticals’ SWOT analysis: Rezdiffra success drives stock potentialMarch 14, 2025 | investing.comWintrust Investments LLC Purchases 900 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)March 14, 2025 | marketbeat.comMadrigal Pharmaceuticals Announces Changes to Board of DirectorsMarch 13, 2025 | msn.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Sold by Erste Asset Management GmbHMarch 13, 2025 | marketbeat.comMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Purchased by Connor Clark & Lunn Investment Management Ltd.March 13, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLABU, MDGL, ARWR, and LABD Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$12.27 -0.47 (-3.69%) As of 03:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Direxion Daily S&P Biotech Bear 3x Shares NYSEARCA:LABD$10.42 +0.99 (+10.48%) As of 03:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.The Direxion Daily S&P Biotech Bear 3X Shares (LABD) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund provides daily 3 times inverse exposure to the S&P Biotechnology Select Industry Index. LABD was launched on May 28, 2015 and is managed by Direxion.Direxion Daily S&P Biotech Bull 3x Shares NYSEARCA:LABU$54.57 -6.40 (-10.50%) As of 03:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.The Direxion Daily S&P Biotech Bull 3X Shares (LABU) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund provides daily 3 times exposure to the S&P Biotechnology Select Industry Index. LABU was launched on May 28, 2015 and is managed by Direxion.Madrigal Pharmaceuticals NASDAQ:MDGL$324.78 -6.45 (-1.95%) As of 03:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Amazon Falls Back to a Key Support Line: Here's How to Play It Berkshire Hathaway Gains Defy Stock Market Slump Tech Sell-Off Makes Microsoft Stock Look Like a Steal Palantir Stock Builds Momentum on New Partnership Amprius Market Gets Amped Up on Growth Outlook 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
